1-(4-bromo-1H-pyrazol-1-yl)-2-methylpropan-2-ol – (1008510-87-9)

PMX 205, 514814-49-4, PMX-205, Hydrocinnamate-(orn-Pro-dcha-Trp-Arg), PMX205, DC25O3L7KZ, LP-16, UNII-DC25O3L7KZ, Cyclic hexapeptide complement C5a antagonist, N-[(3S, 9S, 12S, 15R, 18S)-15-(cyclohexylmethyl)-9-[3-(diaminomethylideneamino)propyl]-12-(1H-indol-3-ylmethyl)-2, 8, 11, 14, 17-pentaoxo-1, 7, 10, 13, 16-pentazabicyclo[16.3.0]henicosan-3-yl]-3-phenylpropanamide, ALS-205, CHEBI:144869, hydrocinnamate-cyclo(ornithyl-prolyl-D-cyclohexylalanyl-tryptophyl-arginyl), (5->1)-lactam-N(2)-(1-oxo-3-phenylpropyl)-L-ornithyl-L-prolyl-3-cyclohexyl-D-alanyl-L-tryptophyl-L-arginine, N-[(3R, 6S, 9S, 15S, 20aS)-9-(3-carbamimidamidopropyl)-3-(cyclohexylmethyl)-6-(1H-indol-3-ylmethyl)-1, 4, 7, 10, 16-pentaoxoicosahydropyrrolo[1, 2-a][1, 4, 7, 10, 13]pentaazacyclooctadecin-15-yl]-3-phenylpropanamide, HC-[OP(D-Cha)WR], N-((3R, 6S, 9S, 15S, 20aS)-9-(3-carbamimidamidopropyl)-3-(cyclohexylmethyl)-6-(1H-indol-3-ylmethyl)-1, 4, 7, 10, 16-pentaoxoicosahydropyrrolo(1, 2-a)(1, 4, 7, 10, 13)pentaazacyclooctadecin-15-yl)-3-phenylpropanamide, N-((3S, 9S, 12S, 15R, 18S)-15-(cyclohexylmethyl)-9-(3-(diaminomethylideneamino)propyl)-12-(1H-indol-3-ylmethyl)-2, 8, 11, 14, 17-pentaoxo-1, 7, 10, 13, 16-pentazabicyclo(16.3.0)henicosan-3-yl)-3-phenylpropanamide, C5a receptor peptide antagonist, GTPL5762, SCHEMBL12971708, EX-A5705, PVA81449, AKOS040735090, DA-56943, HY-110136, CS-0032991, G79478, 851-045-5, N-((3R, 6S, 9S, 15S, 20AS)-6-((1H-indol-3-yl)methyl)-3-(cyclohexylmethyl)-9-(3-guanidinopropyl)-1, 4, 7, 10, 16-pentaoxoicosahydropyrrolo[1, 2-a][1, 4, 7, 10, 13]pentaazacyclooctadecin-15-yl)-3-phenylpropanamide